SCN2A and developmental and epileptic encephalopathy: Here, we describe a female patient with early-onset DEE caused by a GoF variant in SCN2A treated with multiple intrathecal administrations of elsunersen (PRAX-222), an allele-nonselective gapmer ASO targeting SCN2A mRNA.